IncellDx technology combines a unique multiplex RNA in situ hybridization method called Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ (SUSHI) with a novel, cell-based instrument capable of quantifying multiple proteins and molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The company currently has more than 30 issued and pending patents.
The technology is ultra-fast, inexpensive, highly reproducible, and able to perform complex molecular testing without DNA extraction or amplification.
No Positions Available at This Time
CEO & Founder
Dr. Patterson received his undergraduate training in molecular biology from the University of Michigan in Ann Arbor. He then went on to Northwestern University Medical School for training in medicine. During the early stages of the AIDS epidemic, Dr. Patterson began investigating cellular reservoirs of HIV-1 using molecular and in situ technology patented in his laboratory. Dr. Patterson went on to a residency in Pathology focusing on viral pathogenesis. While in his residency, Dr. Patterson determined that enough HIV virus was present in infected individuals to account for the massive destruction of the immune system. This paradigm altering work was published in Science in 1993. Dr. Patterson later was named Chief Resident of Pathology at Northwestern Memorial Hospital. Dr. Patterson has authored over 100 manuscripts and book chapters and he continues his work on HIV-1 pathogenesis and reservoirs at Stanford University School of Medicine. Dr. Patterson was the Medical Director of Diagnostic Virology at Stanford University Hospitals and Clinics.
Chief Technical Officer
Grace has over twenty years experience in Research & Development and Manufacturing Management in the Medical Device industry. She previously served as Project Manager for Dako, leading international product development teams to launch biological reagents and instrument systems. Earlier, she was responsible for the manufacture and quality control of all molecular pathology reagents manufactured by Dako North America, and has led numerous cross-disciplinary teams to develop molecular pathology probes and detection systems. Knutson previously held staff research positions in virology research laboratories at University of California Santa Barbara and USC Medical School. She received her BA from the University of California at Santa Barbara, and holds a Project Management Professional (PMP®) credential.
Chief Business Officer
As Chief Business Officer, Chris Meda has thirty years of leadership in the diagnostic and pharmaceutical industries. Her management responsibilities have included the creation of strategic business direction and plans; operations and commercialization of more than thirty products for various disease areas at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics and Schering AG pharmaceuticals. Chris also serves as a Chair on Women in BIO – San Francisco Chapter, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and as Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Prior to IncellDx, Chris was President of Response Genetics (RGI), a precision medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers.
Chief Marketing Officer
Dr. Blum has over twenty-five years’ experience in the medical/healthcare industry, where he served as a senior executive overseeing marketing, strategic business development and clinical trials for a variety of companies including Specialty Laboratories and Pathology, Inc. In these roles, he has helped develop ad commercialize hundreds of new or enhanced assays in the fields of oncology, immunology, infectious disease, genetics, cardiology, endocrinology, neurology, gastroenterology and women’s health, and strategically positioned the organizations for
growth and increased valuation.
Dr. Blum has lectured internationally on the latest developments in personalized medicine, biotechnology, and laboratory science, and has published extensively. He has served as an advisor on the Molecular and Oncology Advisory Boards for Roche Diagnostics, Editorial Advisor to Clinical Lab Products magazine, and on the Board of Directors for the California Medical Technology Association’s Education & Research
Corporation. He has also been a judge for the prestigious International Health & Medical Media Awards.
Dr. Blum received his Bachelor of Science degree in Biology from UCLA before attending UCLA’s School of Dentistry. After completing two years with honors, he switched fields and obtained his Master of Science degree in Physics from California State University, Northridge, and then earned his Ph.D. in Biophysics from UC Berkeley.
VP of Product Development and Flow
Amruta has 8 years of experience in Clinical Assay Development on Flow Cytometers. Prior to joining the team, she worked as Supervisor in BD Biosciences, leading efforts for the assay development for cancer. Before BD, she worked with Beckman Coulter as a Scientist to develop assays on Flow Cytometer for clinical applications such as HIV and cancer. She was involved in the entire process from initiation to regulatory submissions and helping with post launch activities. These assays were launched in global markets. Her background of engineering and current experience of science helps to better understand the instrument aspect & accordingly develop the assays. She holds MS in Biomedical Engineering from University of Texas at Arlington, where her research was focused on developing nanoparticles for protein & DNA delivery.
Scientific advisory board
I conducted my PhD studies in the field of Programmed Cell Death in Cancer at the German Cancer Research Center (DKFZ, Heidelberg), and my first postdoctoral training in Systems Biology at the Bioquant Center at the University of Heidelberg. Currently, I hold the position of Associate Professor within the Faculty of Microbiology, and the Masters Program in Bioinformatics and Systems Biology at the University of Costa Rica. Over the past years I have successfully established my own research group, the Systems Biology of Personalized Therapy, and have been responsible for supervising several PhD student, Masters students, and undergraduate students both in biological and computational fields. My research interests include the Systems Biology of miRNA regulation of tumor biology, viral infection and sphingolipid metabolism. We have developed molecular sensors for the study of ZIKV and DENV in living cells with single cell resolution, the role of autophagy in chemotherapy response and we have modeled the sphingolipid metabolic pathway with fluorescent sphingolipid analogues to overcome drug resistance. In addition, we have worked on several applied projects on Human Papiloma virus and the development of a novel test to detect bladder cancer in urine. I have mentored 1 postdoc, 3 PhD students and more than 12 Master Students (past and current).
After holding a variety of executive-level positions in the life sciences industry, John joined Celsee in 2017 to expand the company’s strategy, operations, and commercial efforts. His previous leadership roles include Senior Vice President of Global Applied Commercial Operations at Fluidigm and Vice President of Clinical Sequencing Commercial Operations at Thermo Fisher Scientific (formerly Life Technologies). He was also involved in assembling and scaling commercial organizations, including Pacific Biosciences and Affymetrix, leading to explosive growth in the genomics and sequencing markets. John received a BS from Western Michigan University in Biomedical Sciences and an MS from Arizona State University in Biomedical Engineering.
Dr. Alanee graduated cum laude from the College of Medicine University of Baghdad and completed a fellowship in Urologic Oncology at the Memorial Sloan-Kettering Cancer Center in New York, New York. He has trained nationally and internationally on treating problems of the urinary system. Dr. Alanee previously served as the director of urologic oncology at Southern Illinois University and was the director of bladder cancer treatment and clinical trials program at Henry Ford Health System. While at Henry Ford Health System, he performed many robotic-assisted surgical firsts including the first intracorporeal urinary diversion after cystectomy for bladder cancer. His research interests include disparities in delivery of healthcare, genetic bases of genitourinary cancer, immunotherapy of bladder cancer, and developing biomarkers for bladder and prostate cancer.
The CEO of IncellDx has issued the following Quality Policy Statement:
IncellDx is committed to developing, manufacturing and distributing products that are of the highest quality available to our customers. To that end, we are committed to meeting or exceeding all applicable quality, regulatory and customer requirements. In order to achieve our objectives, the management team and all the employees at IncellDx are dedicated to improving the continued suitability and effectiveness of our quality management system.